Syntenin-1 Exosome Biogenesis Modulation Therapy for Neurodegeneration

Syntenin-1 Exosome Biogenesis Modulation Therapy for Neurodegeneration

10-Dimension Rubric Scoring

Syntenin-1 Exosome Biogenesis Modulation Therapy for Neurodegeneration

10-Dimension Rubric Scoring

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 9/10 | First therapeutic targeting Syntenin-1/exosome biogenesis pathway; no existing therapies target this upstream exosome formation mechanism |
| Mechanistic Rationale | 8/10 | Strong mechanistic link: Syntenin-1 acts as master scaffold for ALIX-dependent exosome biogenesis; alpha-syn, tau, TDP-43 all shown to propagate via exosomes |
| Root-Cause Coverage | 7/10 | Addresses upstream mechanism of pathogenic protein secretion rather than downstream aggregation; reduces exosomal propagation burden |
| Delivery Feasibility | 7/10 | Small molecule inhibitors or peptide blockers could cross BBB; AAV-mediated shRNA possible but requires optimization |
| Safety Plausibility | 7/10 | Exosome biogenesis inhibition must be carefully titrated to avoid impairing normal neuronal communication; therapeutic window exists |
| Combinability | 8/10 | Synergizes with aggregation inhibitors, autophagy enhancers, and microglia modulators; addresses secretion component of proteostasis |
| Biomarker Availability | 6/10 | Exosomal protein cargo (p-tau, alpha-syn, TDP-43) in CSF/blood as pharmacodynamic markers; Syntenin-1 levels in extracellular vesicles |
| De-risking Path | 7/10 | In vitro proof in neuron cultures, ex vivo patient-derived iPSC neurons, then IND-enabling studies; clear readouts available |
| Multi-disease Potential | 9/10 | Core mechanism relevant to AD (tau exosomal spread), PD (alpha-syn exosomal spread), ALS (TDP-43 exosomal spread), FTD (TDP-43/tau) |
| Patient Impact | 8/10 | Addresses progressive spread of pathology; could slow disease progression in early-to-moderate stage patients |

Total Score: 76/100

Disease Coverage Matrix

| Disease | Coverage Score | Rationale |
|---------|----------------|-----------|
| Alzheimer's Disease | 9 | Tau propagation via exosomes well-documented; Syntenin-1 modulates this pathway |
| Parkinson's Disease | 9 | α-Synuclein secreted via exosomes; Syntenin-1 inhibition reduces burden |
| ALS | 8 | TDP-43 and SOD1 exported in exosomes; pathway relevance established |
| FTD | 8 | TDP-43 and tau propagation; shared exosomal mechanisms |
| Aging | 7 | Exosome biogenesis dysregulation with age; contributes to proteostatic decline |

Category

Novel target (exosome biogenesis)

Therapeutic Target

Primary Target: Syntenin-1 (SDCBP)

Syntenin-1 (also known as SDCBP) is a small PDZ domain-containing scaffold protein that plays a critical role in exosome biogenesis by recruiting ALIX to intraluminal vesicles (ILVs) in multivesicular bodies (MVBs).

Secondary Targets

• ALIX (PD6A) — Essential cofactor for Syntenin-1-dependent exosome formation
• ESCRT-III subunits (CHMP4B/C, CHMP2A) — Downstream effectors of exosome release
• RAB27A/B — Regulators of MVB docking and exosome release (alternative pathway)

Key Mechanism

The Syntenin-ALIX Exosome Biogenesis Pathway

Therapeutic Intervention Points

• Syntenin-1 small molecule inhibitors — Block PDZ domain interactions with ALIX
• ALIX inhibitors — Prevent Syntenin-ALIX complex formation
• Peptide blockers — Synthetic peptides mimicking Syntenin-1's ALIX-binding motif
• RNAi/shRNA — Reduce Syntenin-1 expression via AAV-delivered constructs

Evidence for Therapeutic Relevance

• [Roux et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16543458/) — Original identification of Syntenin-1 as ALIX interactor via BioID
• [Baietti et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22903299/) — Demonstrated Syntenin-SPDP is required for exosome biogenesis in HeLa cells
• [Larios et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32439764/) — Confirmed ALIX- and ESCRT-III-dependent sorting of transmembrane proteins into exosomes
• [Gauthier et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28733926/) — Phosphorylated tau interacts with endosomal system and is secreted in exosomes
• [Emmanouilidou et al., 2010](https://pubmed.ncbi.nlm.nih.gov/21177974/) — Cell-produced α-syn is secreted in exosomes in a calcium-dependent manner
• [Schneider & Simons, 2016](https://pubmed.ncbi.nlm.nih.gov/27797869/) — Exosomes as vehicle for tau propagation between neurons

Rationale

Why This Target?

Comparison to Existing Approaches

| Approach | Mechanism | Limitation |
|----------|-----------|------------|
| Aggregation inhibitors | Block protein aggregation | Doesn't address already-secreted seeds |
| Autophagy enhancers | Increase intracellular clearance | Doesn't reduce secretion |
| Antibody-based immunotherapies | Clear extracellular protein | Requires ongoing administration |
| Syntenin-1 modulation | Reduce exosome production | Novel, requires proof-of-concept |

Combination Therapy Potential

Synergistic Combinations

• Syntenin-1 inhibition reduces exosomal secretion
• Autophagy enhancers increase intracellular clearance
• Combined effect: Reduced pathological burden from both secretion and accumulation

• Exosome reduction + intracellular aggregation prevention
• Two-pronged attack on proteostasis

• Reduces exosomal burden on microglia
• TREM2-LXR modulation improves microglial clearance
• Synergistic restoration of proteostasis

De-risking Path

Preclinical Development

• Screen small molecule inhibitors of Syntenin-1 PDZ domains
• Test in neuron/iPSC cultures from AD/PD patients
• Measure exosomal tau/α-syn secretion via ELISA/Western blot

• Patient-derived iPSC neurons
• Measure reduction in exosomal pathogenic cargo
• Confirm viability and normal cellular function

• GMP synthesis of lead compound
• PK/PD studies in relevant species
• GLP toxicology (rodent + non-rodent)

Clinical Development

• Single ascending dose in healthy volunteers
• Safety, PK, target engagement biomarkers

• Biomarker-enriched patient population
• Primary endpoint: Reduction in CSF exosomal p-tau/α-syn
• Secondary: Clinical efficacy signals

Implementation Roadmap

Immediate Actions (0-6 months)

Near-term Goals (6-18 months)

Long-term Goals (18-36 months)

Risk Assessment

| Risk | Likelihood | Mitigation |
|------|------------|------------|
| Insufficient BBB penetration | Medium | Use medicinal chemistry to optimize logP and polar surface area |
| Excessive exosome inhibition | Medium | Dose-finding with therapeutic window; titrate to partial inhibition |
| Off-target effects | Low | Selectivity screening; PDZ domain isoform selectivity |
| Lack of efficacy in humans | Unknown | Use patient-derived iPSCs for validation; biomarker enrichment |

References

Related Pages

• [Exosome Biogenesis Mechanism](/mechanisms/exosome-biogenesis)
• [Extracellular Vesicles in Neurodegeneration](/mechanisms/extracellular-vesicles)
• [Alpha-Synuclein Exosomal Secretion](/mechanisms/alpha-synuclein-exosomal-secretion)
• [Tau Propagation Pathways](/mechanisms/tau-propagation)
• [ESCRT-III Neuroprotection Therapy](/ideas/payload-escrthost-III-neuroprotection-therapy)
• [Extracellular Vesicle Neuroprotective Therapy](/ideas/extracellular-vesicle-neuroprotective-therapy)